Skip to main content
main-content

01.12.2014 | Research article | Ausgabe 1/2014 Open Access

The Journal of Headache and Pain 1/2014

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model

Zeitschrift:
The Journal of Headache and Pain > Ausgabe 1/2014
Autoren:
Rosaria Greco, Antonina Stefania Mangione, Giorgio Sandrini, Giuseppe Nappi, Cristina Tassorelli
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1129-2377-15-14) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare to have no competing interests.

Authors’ contributions

RG instructed the experiments, ASM performed the experiments. RG analysed the data and drafted the manuscript. CT revised the manuscript. All authors contributed to the idea of the study, and read and approved the final manuscript.

Abstract

Background

Experimental animal models of migraine have suggested the existence of interactions between the endocannabinoid system and pain mediation in migraine. Extensive evidence has demonstrated a role for the cannabinoid-1 (CB1) receptor in antinociception. However, recent research suggests that also CB2 receptors, especially located outside the central nervous system, play a role in the perception of pain. Systemic administration of nitroglycerin (NTG) consistently induces spontaneous-like headache attacks in migraneurs; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. In this study we evaluated the role of CB2 receptors in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia.

Methods

The study was performed in male Sprague-Dawley rats pre-treated with NTG (10 mg/kg, i.p.) or vehicle (4 hours before) and treated with the CB2 agonist AM1241 o dimethylsulfoxide (DMSO) 60 minutes before both the tail flick test and the formalin test.

Results

AM1241 showed a significant analgesic effect in baseline conditions in both tests. Furthermore, when administered 3 hours after NTG administration, AM1241 at both doses significantly reduced the total number of flinches/shakes during phase II of the test.

Conclusion

These findings suggest that the pharmacological manipulation of the CB2 receptor may represent a potential therapeutic tool for the treatment of migraine.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

The Journal of Headache and Pain 1/2014 Zur Ausgabe

Reviewer Acknowledgement

Acknowledgements to referees 2013

Neu im Fachgebiet AINS

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update AINS und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise